Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients

Daniela Damiani, Renato Fanin, Federico Silvestri, Stefania Grimaz, Laura Infanti, Antonella Geromin, Michela Cerno, Mariagrazia Michieli, Cristina Rinaldi, Chiara Savignano, Gabriella Trani, Mauro Fiacchini, Michele Baccarani

Research output: Contribution to journalArticle

Abstract

Although a large amount of data is available on the effects of filgrastim (granulocyte colony-stimulating factor [G-CSF]) on the mobilization of stem cells in the circulation, data concerning its effects on bone marrow (BM) harvesting is scarce and controversial. We have designed a randomized trial comparing filgrastim-mobilized peripheral blood stem cell (PBSC) transplantation with filgrastim-primed autologous bone marrow transplantation (ABMT). Fifty-five patients affected by non-Hodgkin's (n = 38) or Hodgkin's (n = 17) lymphoma, selected for autologous transplantation over a 12-month period in a single institution, were randomized 2:1 to undergo BM or PB harvest/collection after priming for 3 days with filgrastim, 16 μg/kg body weight dally subcutaneously. BM priming with G-CSF allowed the harvest of a significantly higher number of mononuclear cells (MNC) (0.53 x 108/kg, range, 0.32 to 1.40), as compared with a historical control of unprimed BM harvests (0.43 x 108 MNC/kg, range, 0.15 to 0.72, P = .001). After high-dose ablative therapy, median time to neutrophil recovery above 0.5 x 109/L was 12 days for BM and 11 days for PB (P = .219); median time to platelet recovery above 20 x 109/L was 13 days for BM and 11 days for PB (P = .242). The same number of red blood cells, platelet transfusions, and posttransplant G-CSF doses were required in the two groups of patients. Less patients (50% v 70%) became febrile in the group transplanted with mobilized PB, but days of fever/patient and days on antibiotics were overlapping. The median time spent in the hospital after reinfusion was 16.5 and 15.5 days after primed BM and primed PB, respectively (P = .134). These data suggest that in patients with lymphoma submitted to autologous transplantation, the reinfusion of filgrastim-primed BM or filgrastim-mobilized PB leads to similar results, with an advantage of only 1 day in the neutrophil recovery and 1 day on the time spent in the hospital in favor of primed PB. Either option can be chosen on the basis of the availability of a surgery room or cell separator facilities and considering the patients' characteristics and wishes.

Original languageEnglish
Pages (from-to)36-42
Number of pages7
JournalBlood
Volume90
Issue number1
Publication statusPublished - Jul 1 1997

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients'. Together they form a unique fingerprint.

  • Cite this

    Damiani, D., Fanin, R., Silvestri, F., Grimaz, S., Infanti, L., Geromin, A., Cerno, M., Michieli, M., Rinaldi, C., Savignano, C., Trani, G., Fiacchini, M., & Baccarani, M. (1997). Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients. Blood, 90(1), 36-42.